Tapani Keranen

Dr. Tapani Keranen

University of Eastern Finland, Finland

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2013 in Telemedicine and e-Health
Verified
Journal Article
Closed access
TKTapani Keranen
Tapani Keranen
SLSammeli Liikkanen
Sammeli Liikkanen
Parkinson's disease (PD) is a neurodegenerative disorder in which drug dosing regimens become increasingly complicated with the progression of the disease. This poses a significant risk of nonadherence to drug dosing and a failure in treatment response. We hypothesized that a medication reminder delivered by short message service (SMS) could be one way to ameliorate the problem of medication errors. We conducted an open feasibility study in 50 patients with advanced PD. The subjects set up the process to receive reminders by a Web tool, after which they started to receive automatically transmitted text messages as a medication reminder for 4 weeks. In total, 35 of 50 subjects (70.0%) were able to set up the reminder system without any help. The majority (69%) of the subjects rated the set-up process as “very easy” or “easy.” Almost all (41 subjects, 91%) felt that SMS reminders worked well for them, and only 4 subjects (9%) felt that SMS texts were totally valueless. Almost half of the subjects (22 of 45, 49%) considered that there were clear benefits, and an additional 17 subjects (38%) enjoyed some benefits in using the medication reminder system. Our results indicate that an SMS medication reminder system is a feasible method, even in subjects with advanced PD.

12 December 2013 in BMC Medical Ethics
Verified
Journal Article
Open access
PDF file
AHArja Halkoaho
Arja Halkoaho
MMMari Matveinen
Mari Matveinen
VLVille Leinonen
Ville Leinonen
KLKirsi Luoto
Kirsi Luoto
TKTapani Keranen
Tapani Keranen
In clinical research scientific, legal as well as ethical aspects are important. It is well known that clinical investigators at university hospitals have to undertake their PhD-studies alongside their daily work and reconciling work and study can be challenging. The aim of this project was to create a web based course in clinical research bioethics (5 credits) and to examine whether the method is suitable for teaching bioethics. The course comprised of six modules: an initial examination (to assess knowledge in bioethics), information on research legislation, obtaining permissions from authorities, writing an essay on research ethics, preparing one’s own study protocol, and a final exam. All assignments were designed with an idea of supporting students to reflect on their learning with their own research.

1 July 2010 in Arzneimittelforschung
Verified
Journal Article
Closed access
PDF file
TKTapani Keranen
Tapani Keranen
ASAnnamari Sorri
Annamari Sorri
EMEeva Moilanen
Eeva Moilanen
PYPauli Ylitalo
Pauli Ylitalo
The effects of single and repeated doses of oral activated charcoal (OAC) on the absorption and elimination of the antiepileptic drugs, lamotrigine (CAS 84057-84-1, LTG, Lamictal™) and oxcarbazepine (CAS 28721-07-5, OXC, Trileptal™) were studied in healthy volunteers to assess the therapeutic potential of OAC in the treatment of LTG and OXC overdose. In three open, randomized, cross-over sessions with ≥14 days wash-out, LTG 100 mg and OXC 600 mg were given orally, each to 6 subjects. In one session the drugs were given alone, and in two others with single (50 g) or repeated (20 g) doses of OAC as water suspension. The single OAC dose was given 30 min after the drugs, and repeated doses 6–72 h after LTG and 12–48 h after OXC. Serumconcentrations of the parent drugs as well as those of the pharmacolocigally active metabolite of OXC, 10,11-dihydro-10-hydroxy-carbamazepine (MHD), were measured with reverse-phase highper-formance liquid chromatography. Pharmacokinetic variables were calculated by non-compartmental analysis. Single OAC dose decreased AUC0–∞ of LTG, OXC and MHD to 58%, 2.8% and 4.2% of the respective variables without OAC. Also T max of OXC and MHD decreased to 4.4% and 8.1%, respectively. Repeated OAC doses after LTG decreased its AUC from 6 h to infinity (AUC6–∞) to 39% and t1/2β to 44%. Repeated OAC doses after a single dose of OXC decreased the AUC12–∞ and t1/2β of MHD to 46% and 45% of the respective variables without OAC. OAC greatly reduces gastrointestinal absorption of LTG and especially that of OXC, and it accelerates the elimination of LTG and MHD. The use of OAC is hence strongly favoured in the treatment of overdose with these drugs.

29 September 2017 in Trials
Verified
Journal Article
Open access
PDF file
EREmmi Reijula
Emmi Reijula
APAnna-Maija Pietilä
Anna-Maija Pietilä
AHArja Halkoaho
Arja Halkoaho
TSTuomas Selander
Tuomas Selander
KMKirsti Martikainen
Kirsti Martikainen
TKTapani Keranen
Tapani Keranen
Clinical trials (CTs) are the “gold standard” to ensure the development of new effective treatments in medicine. A study was conducted to assess knowledge of, and attitudes toward, clinical trials among patients with Parkinson’s disease (PD), along with factors that motivate them to participate. A 50-item questionnaire on the views of patients with PD about CTs was developed. It included statements that the respondents assessed on a Likert scale from 1 (“strongly disagree”) to 5 (“strongly agree”). The questionnaire was mailed to a random sample (n = 2000) of members of the patient organization the Finnish Parkinson Association. In all, 708 response forms were returned, of which 681 were accepted after exclusion (a 34% response rate). In general, attitudes of patients with PD toward CTs were positive. Older subjects and patients with lower education levels had inadequate knowledge of general issues related to CTs. Older age, low level of education, and lower number of PD medications were significant predictors for failure to understand the nature and purpose of clinical research. Additionally, significant positive correlation was found between education level and willingness to participate in CTs. Patients with PD have important gaps in their knowledge of methodological issues associated with CTs. The oldest subjects and those with a low level of education have the greatest information needs. Investigators should pay more attention to ensuring the comprehensibility of the information provided to potential CT participants.

1 August 2018 in Seizure: European Journal of Epilepsy
Verified
Journal Article
Closed access
EREmmi Reijula
Emmi Reijula
AHArja Halkoaho
Arja Halkoaho
APAnna-Maija Pietilä
Anna-Maija Pietilä
TSTuomas Selander
Tuomas Selander
KMKirsti Martikainen
Kirsti Martikainen
TKTapani Keranen
Tapani Keranen

19 September 2012 in International Journal Of Clinical Practice
Verified
Journal Article
Closed access
PDF file
TKTapani Keranen
Tapani Keranen
TMT. Mattila
T. Mattila
TLT. Luukkaala
T. Luukkaala
HKH. Kuusisto
H. Kuusisto